Chen Teresa K., Fitzpatrick Jessica, Winkler Cheryl A., Binns-Roemer Elizabeth A., Corona-Villalobos Celia P., Jaar Bernard G., Sozio Stephen M., Parekh Rulan S., Estrella Michelle M.
To better understand the impact of APOL1 risk variants in end-stage renal disease (ESRD) we evaluated associations of APOL1 risk variants with subclinical cardiovascular disease (CVD) and mortality among African Americans initiating hemodialysis and enrolled in the Predictors of Arrhythmic and Cardiovascular Risk in ESRD cohort study.